In addition, DOK2 deficiency in ovarian cancer induced carboplatin resistance by inhibiting the apoptosis of tumor cells [38], while the expression of DOK2/Ras p21 protein activator 1 was associated with prognosis and quality of life of breast cancer patients. This evidence concerns the gene RASA1 and ovarian carcinoma.